7-azaindoles, pharmaceutical compositions and their therapeutic applications

US7541464B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Stefanie Keil · Frankfurt am Main, DE
• Maike Glien · Frankfurt am Main, DE
• Hans-Ludwig Schaefer · Frankfurt am Main, DE
• Wolfgang Wendler · Bad Camberg, DE
• Patrick Bernardelli · Fontenay-aux-Roses, FR
• Corinne Terrier · Livry-Gargan, FR
• Baptiste Ronan · Clamart, FR

Key dates

• Filing date: Mar 5, 2007
• Grant date: Jun 2, 2009
• Expiry date: Mar 5, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P29/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates generally to compounds and compositions for the treatment of metabolic diseases and specifically, the present invention relates to compounds that therapeutically modulation and control lipid and/or carbohydrate metabolism and are thus suitable for the prevention and/or treatment of diseases such as type 2 diabetes, atherosclerosis, and the diverse manifestations thereof. The present invention relates to 7-azaindoles, their physiologically acceptable salts and functional derivatives thereof that exhibit a high degree of peroxisome proliferator-activated receptors (PPAR) agonist activity. Compounds of the present invention are described by formula I:in which the R-groups are herein defined, together with their pharmaceutically acceptable salts, therapeutic methods for their use and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.